Related Experiment Video
Updated: Aug 7, 2026
09:37
A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
Relationship between genotype and function of the human CYP1A1 gene
1Institute of Environmental Medicine, New York University Medical Center, New York 10987.
Journal of Toxicology and Environmental Health
|October 1, 1993
Summary
This study found distinct human CYP1A1 genotypes across racial groups, revealing a link between specific CYP1A1 gene variants and increased enzyme activity, impacting the metabolism of carcinogens.
Area of Science:
- Pharmacogenomics
- Molecular Biology
- Human Genetics
Background:
- Cytochrome P450 1A1 (CYP1A1) is crucial for metabolizing environmental toxins, including carcinogenic polycyclic aromatic hydrocarbons.
- Genetic variations (polymorphisms) in CYP1A1 can alter enzyme activity and influence individual susceptibility to diseases.
Purpose of the Study:
- To investigate the frequencies of CYP1A1 genetic polymorphisms in diverse populations.
- To determine the relationship between CYP1A1 genotype and its enzymatic function.
Main Methods:
- Restriction fragment length polymorphism (RFLP) analysis to identify CYP1A1 genotypes.
- Ethoxyresorufin O-deethylase (EROD) assay to measure lymphocyte CYP1A1 enzyme activity.
Main Results:
- Significantly higher frequencies of a variant Msp1 polymorphism in Asians compared to European-Americans; African-American frequencies were similar to Asians.
- Variant genotypes at the Msp1 locus were more frequent than at a polymorphic site in exon 7.
- Elevated inducible CYP1A1 enzyme activity was observed in individuals with variant exon 7 genotypes.
Conclusions:
- Demonstrated racially distinct patterns of CYP1A1 genotypes.
- Established a functional link between CYP1A1 genotype and catalytic activity, affecting the metabolism of polycyclic aromatic hydrocarbons.
Related Concept Videos
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...